| Drug NDC: | 43742-0977 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Allermilk |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Taraxacum Officinal, Hydrastis Canadensis, Apiolum, Asparagine, Benzoicum Acidum, Cholinum, Cinnamic Acid, Coumarinum, Eugenol, Folic Acid, Folliculinum, Formalinum, Gaba (gamma-aminobutyric Acid), Histaminum Hydrochloricum, Menadione, Octopamine (hydrochloride), Oophorinum (suis), Phenyl Isothiocyanate, Piperine, Progesterone, Quercetin, Rutin, Saccharum Lactis, Vanillylamine, Xanthine |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Deseret Biologicals, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | .GAMMA.-AMINOBUTYRIC ACID - 6 [hp_X]/mL APIOLE (PARSLEY) - 6 [hp_X]/mL ASPARAGINE - 6 [hp_X]/mL BENZOIC ACID - 6 [hp_X]/mL CHOLINE - 6 [hp_X]/mL CINNAMIC ACID - 6 [hp_X]/mL COUMARIN - 6 [hp_X]/mL ESTRONE - 6 [hp_X]/mL EUGENOL - 6 [hp_X]/mL FOLIC ACID - 6 [hp_X]/mL Load more... GOLDENSEAL - 6 [hp_X]/mL HISTAMINE DIHYDROCHLORIDE - 6 [hp_X]/mL LACTOSE, UNSPECIFIED FORM - 6 [hp_X]/mL MENADIONE - 6 [hp_X]/mL OCTOPAMINE HYDROCHLORIDE - 6 [hp_X]/mL PHENYL ISOTHIOCYANATE - 6 [hp_X]/mL PIPERINE - 6 [hp_X]/mL PROGESTERONE - 6 [hp_X]/mL QUERCETIN - 6 [hp_X]/mL RUTIN - 6 [hp_X]/mL SUS SCROFA OVARY - 6 [hp_X]/mL TARAXACUM OFFICINALE - 3 [hp_X]/mL VANILLYLAMINE - 6 [hp_X]/mL XANTHINE - 6 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 17 Feb, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 22 May, 2023 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 12 Jun, 2026 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Deseret Biologicals, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000175806 N0000175807 N0000185508 N0000175629 N0000184306 M0000728 M0017672 N0000175601 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 2ACZ6IPC6I QQ67504PXO 5Z33R5TKO7 8SKN0B0MIM N91BDP6H0X U14A832J8D A4VZ22K1WT 2DI9HA706A 3T8H1794QW 935E97BOY8 Load more... ZW3Z11D0JV 3POA0Q644U J2B2A4N98G 723JX6CXY5 37YAS5L9HQ 0D58F84LSU U71XL721QK 4G7DS2Q64Y 9IKM0I5T1E 5G06TVY3R7 S7YTV04R8O 39981FM375 1WEZ91E3Z0 1AVZ07U9S7 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Ammonium Ion Binding Activity [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Nitrogen Binding Agent [EPC] Standardized Chemical Allergen [EPC] Progesterone [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Progesterone [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Ammonium Ion Binding Activity [MoA] Cell-mediated Immunity [PE] Increased Histamine Release [PE] Nitrogen Binding Agent [EPC] Progesterone [CS] Progesterone [EPC] Standardized Chemical Allergen [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 43742-0977-1 | 30 mL in 1 BOTTLE, DROPPER (43742-0977-1) | 17 Feb, 2017 | 22 May, 2023 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.